June 7, 2013Annals of MedicineOpen Access

Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays

View Full Paper

Ask AI

Bookmark

Population

Patients taking rivaroxaban who require laboratory testing in special clinical circumstances

Design

Review

Authors

ELEdelgard Lindhoff‐LastVascular Medicine JAJack AnsellPreventive Cardiology TSTheodore E. SpiroBayer (United States)

Discussion

Member takes

Implication

May guide rivaroxaban testing in select cases; leaves open prospective outcome validation.

Structured PICO

Population

Patients taking rivaroxaban who require laboratory testing in special clinical circumstances (e.g., suspected overdose, bleeding or thromboembolic event, acute renal failure, or urgent surgery)

Intervention

Laboratory testing of rivaroxaban using quantitative (anti-Factor Xa method) and qualitative (prothrombin time) measurements

Provides practical guidance on when and how to measure rivaroxaban exposure using anti-Factor Xa and prothrombin time assays in special clinical circumstances.

Cite This Study

Lindhoff‐Last et al. (2013) studied this question.

synapsesocial.com/papers/6a76e58cde5e3adfbdf6d997 https://doi.org/10.3109/07853890.2013.801274

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider